Plasma biomarkers for afatinib monotherapy in EGFR-mutated non-small cell lung cancer: Novel insights from companion genomics analysis of the EXTRA study
This is the first large-scale prospective study of NGS-based concurrent testing for plasma cfDNA and evDNA mutations. The findings suggest that cfDNA mutation status is a promising plasma biomarker for afatinib monotherapy.
Authors
- Nagio Takigawa (ORCID: https://orcid.org/0000-0002-3835-5128)
- Yusuke Okuma (ORCID: https://orcid.org/0000-0001-5743-0149)
- Aya Hirata (ORCID: https://orcid.org/0000-0003-1439-4242)
- Toshiya Maekura (ORCID: https://orcid.org/0000-0003-0344-5227)
- Kenzo Soejima (ORCID: https://orcid.org/0000-0001-9749-995X)
- Hisashi Tanaka (ORCID: https://orcid.org/0000-0003-2009-0210)
- Tomonori Makiguchi (ORCID: https://orcid.org/0000-0001-9249-7904)
- Makoto Endoh (ORCID: https://orcid.org/0000-0001-7763-1423)
- Kazuma Kishi (ORCID: https://orcid.org/0000-0002-6801-0147)
- Koji Ueda (ORCID: https://orcid.org/0000-0001-9066-4959)
- Takeo Endo
- Akikazu Kawase (ORCID: https://orcid.org/0000-0002-1736-3874)
- Yoshiro Nakahara (ORCID: https://orcid.org/0000-0001-5579-4491)
- Shigeru Tanzawa (ORCID: https://orcid.org/0000-0001-5738-0313)
- Kageaki Watanabe (ORCID: https://orcid.org/0000-0002-8420-5606)
- Akira Togashi
- Noriyuki Matsutani (ORCID: https://orcid.org/0000-0002-4296-8410)
- Nobuhiko Seki (ORCID: https://orcid.org/0000-0002-6562-1137)
- Akihiro Bessho (ORCID: https://orcid.org/0000-0002-0394-7377)
- Hiroki Shinchi
- Hiroyuki Yasuda (ORCID: https://orcid.org/0000-0002-7077-0655)
- Yoshitaka Seki (ORCID: https://orcid.org/0000-0002-4108-9350)
- Hidetoshi Itani (ORCID: https://orcid.org/0009-0006-2007-4666)
- Kentaro Hayashi (ORCID: https://orcid.org/0000-0002-2936-9544)
- Nobumasa Takahashi (ORCID: https://orcid.org/0000-0003-0758-6035)
- Kei Morikawa (ORCID: https://orcid.org/0000-0002-0745-5118)
- Hideyuki Nakagawa (ORCID: https://orcid.org/0000-0002-5497-1860)
- Kenji Nemoto (ORCID: https://orcid.org/0000-0002-9374-8274)
- Kiyoshi Takeyama (ORCID: https://orcid.org/0000-0002-1734-0031)
- Kazuya Horiuchi
- Tetsuya Okano
Institutions
- Nihon University (JP)
- Hirosaki University (JP)
- Tokyo Medical University (JP)
- St. Marianna University School of Medicine (JP)
- Kawasaki Medical School (JP)
- Kyorin University (JP)
- Keio University (JP)
- Saitama Prefecture (JP)
- Tokyo Metropolitan Komagome Hospital (JP)
- Hamamatsu University School of Medicine (JP)
- Hoshigaoka Medical Center (JP)
- National Hospital Organization Mito Medical Center (JP)
- Teikyo University Hospital (JP)
- SHOWA Medical University Northern Yokohama Hospital (JP)
- Keio University Hospital (JP)
- The Jikei University Hospital (JP)
- Okayama Red Cross General Hospital (JP)
- Boehringer Ingelheim (Japan) (JP)
- Yamagata Prefectural Central Hospital (JP)
- Tokyo Women's Medical University (JP)
- National Hospital Organization (JP)
- Ibarakihigashi National Hospital (JP)
- Hirosaki National Hospital (JP)
- Ise Red Cross Hospital (JP)
- Toranomon Hospital (JP)
- Japanese Foundation For Cancer Research (JP)
- Kitasato University (JP)
- Teikyo University (JP)
Publication Details
- Journal
- Cancer Treatment and Research Communications
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1016/j.ctarc.2025.100952
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Boehringer Ingelheim